Connect with us


Current news: Nanoparticles delivered past the Blood Brain Barrier



The circus is coming to town…

Jon Rappoport Jan 31

The circus is coming to town. Your brain is the circus, and the town is the lab.

The nanoparticle elephants and lions and clowns they want to put in your brain are only a billionth of a meter in size. That’s right. If you stack 80,000 of the particles side by side, they add up to the width of a human hair.

But don’t worry. The scientists know what they’re doing. They have to. No one else does.

You’ll feel fine. Better than ever.

Because this is medical. And medical always works.

Ask a person over the age of 65 who was diagnosed with COVID after a phony useless test and sedated and put on a breathing ventilator in a hospital. You’ll have to reach into the afterlife to talk to him because the treatment killed him.

But that’s OK. Everything is OK.

Science Daily reports (Jan 19, 2023):

Gene therapies have the potential to treat neurological disorders like Alzheimer’s and Parkinson’s diseases, but they face a common barrier—the blood-brain barrier. Now, researchers at the University of Wisconsin-Madison have developed a way to move therapies across the brain’s protective membrane to deliver brain-wide therapy with a range of biological medications and treatments.

“There is no cure yet for many devastating brain disorders,” says Shaoqin “Sarah” Gong, UW-Madison professor of ophthalmology and visual sciences and biomedical engineering and researcher at the Wisconsin Institute for Discovery. “Innovative brain-targeted delivery strategies may change that by enabling noninvasive, safe and efficient delivery of CRISPR genome editors that could, in turn, lead to genome-editing therapies for these diseases.”

CRISPR is a molecular toolkit for editing genes (for example, to correct mutations that may cause disease), but the toolkit is only useful if it can get through security to the job site. The blood-brain barrier is a membrane that selectively controls access to the brain, screening out toxins and pathogens that may be present in the bloodstream. Unfortunately, the barrier bars some beneficial treatments, like certain vaccines and gene therapy packages, from reaching their targets because it lumps them in with hostile invaders…

In a study recently published in the journal Advanced Materials, Gong and her lab members, including postdoctoral researcher and first author of the study Yuyuan Wang, describe a new family of nano-scale capsules made of silica that can carry genome-editing tools into many organs around the body and then harmlessly dissolve.

By modifying the surfaces of the silica nanocapsules with glucose and an amino acid fragment derived from the rabies virus, the researchers found the nanocapsules could efficiently pass through the blood-brain barrier to achieve brain-wide gene editing in mice. In their study, the researchers demonstrated the capability of the silica nanocapsule’s CRISPR cargo to successfully edit genes in the brains of mice, such as one related to Alzheimer’s disease called amyloid precursor protein gene.

Because the nanocapsules can be administered repeatedly and intravenously, they can achieve higher therapeutic efficacy without risking more localized and invasive methods.

The researchers plan to further optimize the silica nanocapsules’ brain-targeting capabilities and evaluate their usefulness for the treatment of various brain disorders. This unique technology is also being investigated for the delivery of biologics to the eyes, liver and lungs, which can lead to new gene therapies for other types of disorders.

Uh-huh. Right. Sure. It’s all OK.

I hope you caught the part about sending GENE EDITORS into the brain to perform genetic procedures.

Early in my career, I worked with editors at newspapers and magazines. A number of them were grossly overweight. They wouldn’t fit in a brain.

But you see, THESE groundbreaking editors are nano-sized. A billionth of a meter. And they’re carrying editing tools with them on their belts.

The tools are called CRISPR. That’s the latest and greatest blade that cuts out offending genes.

Only one problem. A number of studies show CRISPR screws up. Particularly at the point where the cut is made. When the genes reconnect to eliminate the empty space that was created, the joining isn’t perfect.

Oops. And this has consequences. Bad consequences. The extent and nature of those new sloppy joinings are unpredictable. Think RIPPLE EFFECT.

That adds to the wildness of the circus in the brain.

You can’t really talk to those nanoparticle gene editors and ask them what went wrong. They don’t know. They’re only equipped to make their CRISPR cuts. Then they (supposedly) dissolve.

Did you also notice, in the Science Daily article above, the reference to delivering life-saving drugs and vaccines directly to the brain?

So now nanoparticle drug humpers will be added to the medical circus. Carrying, for example, vaxes like COVID, which are injuring and killing people across the world. And drugs which routinely kill at least 100,000 American patients every year.

But these consequences are just the cost of doing business behind the WOW super-technology that allows passage through the blood brain barrier.

This innovation is like drilling into a percolating volcano. You do it because you can. This is the guiding principle. When all hell breaks loose, because you just woke up the heat and the fire and the lava, you accept that.

Science marches on.

Stay tuned.

— Jon Rappoport

Episode 34 of Rappoport Podcasts—“We Are Living In the Era of Nanotechnology, Science Beyond Our Control; A Clear and Present Danger”—is now posted on my substack. It’s a blockbuster. To listen, click here. To learn more about This Episode of Rappoport Podcasts, click here.


What Went Right This Week: How The World Got Kinder, And More Good News





Continue Reading


Universal Cancer Immunotherapy May Be Possible Through Protein Engineering | The Optimist Daily





Oncology medicine and cancer treatment concept as a tumor or tumour being treated with white blood cells attacking the disease as an immunotherapy 3D illustration.

Scientists at ETH Zurich have made significant progress in developing a ready-to-use immunotherapy treatment for cancer. A synthetic protein modification can allow immune cells from any donor to be delivered to any patient without the risk of an adverse immunological reaction.

What is immunotherapy?

The human immune system is a robust first line of defense against disease, but cancer has a few sneaky tricks up its sleeve that allow it to hide and avoid elimination. Immunotherapy is a new treatment that gives the immune system the upper hand by supercharging a patient’s immune cells to seek out and destroy cancers.

Typically, the approach involves extracting a patient’s immune cells, genetically modifying them to spot cancer, and reintroducing them into the body. Not only does this require time, which many cancer patients lack, but it isn’t always practical if a patient’s immune system isn’t up to the task.

Immune cells from a healthy patient would be ideal, but this comes with its own set of challenges. Because immune cells are adept at recognizing and attacking “foreign” cells, donated cells frequently end up targeting the recipient’s healthy cells.

What is TCR-CD3?

The ETH Zurich researchers discovered a solution to potentially overcome this obstacle in the latest study, paving the path for standardized, off-the-shelf immunotherapy. The researchers focused on a specific chemical combination known as TCR-CD3, located on the surface of killer T cells, and activate them towards specific antibodies – including both desired triggers such as cancer and unwanted ones on healthy cells.

The researchers developed a synthetic version of the TCR-CD3 complex that prevents killer T cells from attacking healthy cells while yet allowing them to be modified to target cancer cells. So far, laboratory tests on human cells have been positive, with no signs of harmful immunological responses.

While there is still much work to be done, such as testing in human patients, the team believes that the research will eventually lead to a standardized, off-the-shelf cancer therapy product that can be administered to any patient without the need to remove, engineer, and return their own immune cells. This would make it far less expensive, simpler, and faster to roll out to patients.

The researchers have applied for patents and intend to establish a spin-off company to assist in bringing the approach to the market.

The post Universal cancer immunotherapy may be possible through protein engineering first appeared on The Optimist Daily: Making Solutions the News.

Continue Reading


How The UK Became More Liberal, Despite The Culture Wars





Continue Reading